Bastide le Confort Medical (BLC) AI Stock Analysis

• Market Cap: €182.82M
• Dividend Yield: N/A
• Average Volume (3M): 6.30K
• Price to Earnings (P/E): 108.5
• Beta (1Y): 0.84
• Revenue Growth: 3.24%
• EPS Growth: -75.05%
• Country: FR
• Employees: 3,635
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Distribution
• EPS (TTM): 0.08
• Shares Outstanding: 7,365,078
• 10 Day Avg. Volume: 9,104
• 30 Day Avg. Volume: 6,304
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €34.00
• Price Target Upside: 40.50% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 66 Neutral
• Price Target: €34.00 ▲(40.50% Upside)

The stock shows strong technical momentum, which is the most significant factor in the score. However, financial performance concerns, particularly around profitability and leverage, along with valuation challenges due to a high P/E ratio, weigh on the overall score.

Bastide le Confort Medical Business Overview & Revenue Model

Company Description

Bastide le Confort Medical (BLC) is a French company specializing in the distribution and rental of medical equipment and supplies. The company serves healthcare professionals, institutions, and private individuals, offering a wide range of products designed to improve patient care and comfort, including mobility aids, homecare beds, respiratory assistance devices, and various other healthcare-related products.

How the Company Makes Money

Bastide le Confort Medical generates revenue through the sale and rental of medical equipment and supplies. The company's key revenue streams include direct sales to healthcare institutions and private customers, as well as rental services for medical equipment like mobility aids and respiratory devices. BLC also benefits from partnerships with healthcare providers and insurance companies that facilitate the provision and reimbursement of medical products and services. The company leverages its extensive distribution network to maintain a steady flow of products to various market segments, contributing significantly to its earnings.

Bastide le Confort Medical Financial Statement Overview

Summary

Bastide le Confort Medical shows growth in revenue and operational cash flow, but profitability has been inconsistent with recent net losses. The high leverage and fluctuating free cash flows present financial risks that should be monitored closely.

Income Statement

The company experienced steady revenue growth with a CAGR of approximately 9.5% over the past five years, although the recent year saw a slight decrease in gross profit margin. The net income turned negative in the latest year, indicating profitability challenges that need addressing.

Balance Sheet

The company maintains a high debt-to-equity ratio of 5.12 in 2024, indicating significant leverage which poses risk. However, the equity ratio has been relatively stable, showing some level of balance in the capital structure.

Cash Flow

Free cash flow has been volatile but positive in recent years, with a significant drop from 2023 to 2024. The operating cash flow remains strong relative to net income, although the free cash flow to net income ratio is concerning due to the negative net income.

Breakdown	TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	540.26M	529.75M	508.03M	468.30M	444.07M	382.71M
Gross Profit	51.59M	46.83M	333.73M	306.80M	280.26M	251.61M
EBITDA	114.74M	107.20M	82.36M	79.51M	80.19M	66.67M
Net Income	1.71M	-900.00K	16.07M	13.68M	13.45M	11.60M
Balance Sheet
Total Assets	675.97M	647.07M	657.08M	632.55M	569.11M	506.00M
Cash, Cash Equivalents and Short-Term Investments	31.30M	23.62M	36.71M	22.13M	33.74M	35.42M
Total Debt	420.68M	408.65M	427.39M	419.23M	357.62M	306.29M
Total Liabilities	598.33M	566.34M	568.99M	545.89M	484.05M	426.38M
Stockholders Equity	76.08M	79.77M	87.65M	84.56M	81.31M	75.67M
Cash Flow
Free Cash Flow	14.98M	10.64M	36.65M	-6.51M	19.62M	-179.00K
Operating Cash Flow	82.03M	66.04M	90.28M	46.76M	66.13M	39.61M
Investing Cash Flow	-66.38M	-43.65M	-76.27M	-104.74M	-73.45M	-50.55M
Financing Cash Flow	-20.72M	-35.55M	7.53M	39.81M	9.65M	25.87M

Bastide le Confort Medical Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 24.20
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:BLC, the sentiment is Negative. The current price of 24.2 is below the 20-day moving average (MA) of 25.99, below the 50-day MA of 28.58, and below the 200-day MA of 26.42, indicating a bearish trend. The MACD of -1.05 indicates Negative momentum. The RSI at 41.37 is Neutral, neither overbought nor oversold. The STOCH value of 71.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:BLC.

Bastide le Confort Medical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LNA	70 Outperform	303.23M	13.64	6.95%	4.47%	9.58%	-6.69%
BLC	66 Neutral	€182.82M	108.46	11.71%	―	3.24%	-75.05%
AMPLI	64 Neutral	300.13M	275.33	0.00%	―	16.83%	0.00%
ALERS	62 Neutral	255.14M	63.96	2.24%	―	18.89%	-20.75%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Bastide le Confort Medical Corporate Events

Bastide Group Releases Semi-Annual Financial Report

The Bastide Group has released its semi-annual financial report for December 31, 2024, making it available to the public and filing it with the Autorité des Marchés Financiers. This report can be accessed on their website, and the next financial update will be the publication of the 3rd quarter 2024-2025 revenue on May 15, 2025. This release underscores Bastide’s commitment to transparency and may impact investor relations and market positioning.